Clinical trial
A Study of Indinavir Taken With or Without DMP 266
NCT00002393 · Dupont Merck, Industry · Completed
Key facts
| NCT number | NCT00002393 |
|---|---|
| Title | A Study of Indinavir Taken With or Without DMP 266 |
| Official title | A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy |
| Lead sponsor | Dupont Merck, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Indinavir sulfate, Efavirenz |
| Enrollment | 300 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: